Skip to main content

Peer Review reports

From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

Original Submission
15 Jan 2018 Submitted Original manuscript
3 Apr 2018 Reviewed Reviewer Report - Zong Sheng Guo
24 Apr 2018 Reviewed Reviewer Report - Ashok Dilly
18 Nov 2018 Reviewed Reviewer Report - John Hilton
25 Nov 2018 Reviewed Reviewer Report - Makoto Kubo
4 Jan 2019 Author responded Author comments - Zsuzsanna Kahan
Resubmission - Version 2
4 Jan 2019 Submitted Manuscript version 2
7 Jan 2019 Reviewed Reviewer Report - John Hilton
12 Jan 2019 Reviewed Reviewer Report - Makoto Kubo
23 Jan 2019 Author responded Author comments - Zsuzsanna Kahan
Resubmission - Version 3
23 Jan 2019 Submitted Manuscript version 3
Publishing
29 Jan 2019 Editorially accepted
6 Feb 2019 Article published 10.1186/s12885-019-5329-6

You can find further information about peer review here.

Back to article page